NCT02848131
Senescence in Chronic Kidney Disease
Enrolling by Invitation
PHASE2Ages 40–80InterventionalTreatmentMayo ClinicInvestigator-initiated
~30 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:Group 2: DasatinibGroup 2: Quercetin
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in proportion of senescent cells (representing the total senescent cell burden) present
Measured over Baseline, Day 14
Conditions
Where it's being run
2 sites across 2 statesFlorida1
Minnesota1
Study leadership
- LaTonya J Hickson, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Change in proportion of senescent cells (representing the total senescent cell burden) presentBaseline, Day 14
Assessment of senescence markers in skin, fat, and/or blood at baseline and day 14.